ClinicalTrials.gg
CompletedNCT06548997Updated Aug 14, 2024

A Phase I Study of GZR18 Injection in Healthy Subjects

A Phase 1 interventional study of GZR18 and Placebo in Type 2 Diabetes and Overweight and Obesity, sponsored by Gan and Lee Pharmaceuticals, USA. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-14.

Sponsored by Gan and Lee Pharmaceuticals, USA · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Dec 2021, registered Aug 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing bofanglutide in Diabetes Mellitus, Type 2 — 2 open to participants now, 5 under way, 1 of them phase 3. bofanglutide · Diabetes Mellitus, Type 2.

Enrollment
8th of 10
57 · median 91
Started
2021
the only one that year
Phase 1
4 of 10
1 open now
Registered
4th of 10
by date
Lead sponsor
6 of 10
Gan and Lee Pharmaceuticals, USA

Among the 10 studies testing bofanglutide in Diabetes Mellitus, Type 2, this one is the 8th largest by enrollment, is the only one that started in 2021, is one of 4 in phase 1, and was the 4th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 10 studies testing bofanglutide in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About bofanglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing bofanglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in China. The aim of the trial is to evaluate the safety and tolerability of GZR18 injection in healthy subjects following single dose and once-weekly dose for 2 consecutive weeks until reaching the target dose.

03

Conditions studied

  • Type 2 Diabetes
  • Overweight and Obesity
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Subjects sign voluntarily.
    1. Chinese adult subjects, male or female.
    1. Age 18-55 at screening (both included).
    1. At screening and baseline, 19.0 kg/m2 ≤ ≤ 26.0 kg/m2 (male ≥55.0 kg, female ≥45.0 kg).
    1. Female subjects were human chorionic gonadotophin (HCG) negative at screening and baseline.

Exclusion criteria

Exclusion Criteria:

    1. History of dizziness with blood and needles.
    1. Known or suspected allergy to study related products; or a history of drug and food allergies; or a history of allergy-related diseases.
    1. Participants who participated in other clinical trials and were given the drug or medical device intervention within 90 days prior to screening.
    1. Blood donation, surgery, or trauma with significant blood loss (more than or equal to 400 mL, except for menstrual blood loss in women) within 12 weeks prior to screening.
    1. Any medical history judged by the investigator, including but not limited to: lung, gastrointestinal, liver, nervous system, kidney, genitourinary and endocrine, skin, or blood disorders, especially a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 , and a history of pancreatitis (acute or chronic).
    1. At screening or baseline, physical examination showed clinically significant abnormalities judged by the investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    GZR18

    Drug: GZR18

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • DrugGZR18

    5 μg/kg-maximum tolerated dose (MTD), single dose or two doses

  • OtherPlacebo

    administered the same volume as GZR18

06

What researchers measure

Primary outcomes

  1. TEAE

    Incidence of treatment-emergent adverse events (TEAE)

    Time frame: after 28/35 days of treatment

Secondary outcomes

  1. Cmax

    The peak concentration after reaching the target dose

    Time frame: 28/35 days

  2. AUClast

    the area under the concentration-time curve from 0 to the last time that the concentration can be accurately measured

    Time frame: 28/35 days

  3. AUC0-inf

    the area under the concentration-time curve from 0 to infinity

    Time frame: 28/35 days

  4. Tmax

    the peak time

    Time frame: 28/35 days

  5. λz

    the elimination rate constant

    Time frame: 28/35 days

  6. t1/2

    the half-life

    Time frame: 28/35 days

  7. tlag

    retention time

    Time frame: 28/35 days

  8. CL/F

    apparent clearance rate

    Time frame: 28/35 days

  9. Vz/F

    apparent volume of distribution

    Time frame: 28/35 days

  10. AUC%extra

    extrapolation percentage of AUC0-in

    Time frame: 28/35 days

  11. MRT

    average retention time

    Time frame: 28/35 days

  12. AUCglucose0-14h

    area under the concentration-time curve of fasting blood glucose from 0 to 14 hours after each administration

    Time frame: 28/35 days

  13. AUCc-peptide0-14h

    area under the concentration-time curve of fasting C-peptide from 0 to 14 hours after each administration

    Time frame: 28/35 days

  14. AUCinsulin0-14h

    area under the concentration-time curve of fasting insulin from 0 to 14 hours after each administration

    Time frame: 28/35 days

  15. body weight

    Time frame: 28/35 days

  16. body mass index (BMI)

    Time frame: 28/35 days

07

Study locations

1 site
  • Gan & Lee Pharmaceuticals Co., Ltd
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Oct 2022, 10 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 10 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2024
First posted
Aug 12, 2024
StartActual
Dec 2, 2021
Primary completionActual
Oct 20, 2022
CompletionActual
Oct 20, 2022
Last update
Aug 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06548997
Responsible party
Sponsor
First posted
Aug 12, 2024
Start date
Dec 2, 2021
Primary completion
Oct 20, 2022
Completion
Oct 20, 2022
Last update
Aug 14, 2024

Study contacts

Liyuan Zhao, Ph.D
study director · Gan & Lee Pharmaceuticals.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bofanglutide

Start the discussion